Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (767)	1/31/2000 8:37:00 AM
From: Dr. John M. de Castro	Respond to of 1494

Patient Enrollment Completed in Phase II Trial of Memantine for Treatment Of Dementia in AIDS Patients biz.yahoo.com Best regards John de C

To: John McCarthy who wrote (767)	2/9/2000 11:37:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

NTII is over $7 per share and on the move. There is no news. The news that I expect shortly, is the report of the detailed analysis of the Phase IIb memantine for Diabetic neuropathy trial. The run could be a good sign that the results are even more striking than indicated in the original release. On the other hand the uptick may simply be a reflection of the white hot biotech sector carrying over to NTII. In any case, the continuation of my birthday present is most welcome :-) Best regards John de C